Controversy and Anticipated Changes Surrounding Germany's Medical Cannabis Act

The recent cabinet draft to amend Germany's Medical Cannabis Act has sparked significant critique. The proposal aims to prohibit initial prescriptions via telemedicine and restrict mail-order dispensing by pharmacies. Critics, including prominent media outlets like DIE ZEIT and DER SPIEGEL, argue these measures could hinder patient care and benefit illegal markets. Political dissent within the governing coalition echoes these concerns, highlighting potential discrimination against patients and conflicts with European law.

Cantourage Group SE, a key player in the European medical cannabis market, publicly supports these criticisms. CEO Philip Schetter highlights the draft's risk of pushing patients back to illicit sources, potentially favoring criminal activity. As debates continue, Cantourage plans to enhance its “Telecan” platform, ensuring compliance with regulatory changes and facilitating cannabis therapies.

The unfolding legislative process promises potential amendments, influenced by public petitions and stakeholder hearings that emphasize maintaining accessible cannabis care.